Government

The latest webinar in this series explored challenges and solutions in the current and future landscape of cannabis policies and regulation.

Missouri’s Department of Health and Senior Services is on track to “embargo and condemn” products that contain intoxicating cannabinoids starting September 1, 2024 in accordance to an executive order signed by the state’s governor, Michael L. Parsons.

A recently added amendment to the 2024 Farm Bill would significantly impact intoxicating hemp-derived products.

Focusing on the potential effects for medical cannabis patients, Americans for Safe Access held a high-level presentation and discussion on the rescheduling of cannabis.

The US Attorney General has initiated the process to reclassify cannabis from a Schedule I to a less-restrictive Schedule III substance.

The commission appointed to study a state-run cannabis model concluded its final meeting without issuing recommendations on legislation.

On Wednesday, August 30th, the Department of Health and Human Services made its recommendation to the Drug Enforcement Agency to classify cannabis as a Schedule III drug, paving the way for reform, industry expansion, and research opportunities.

The recently approved legislation creates new opportunities for possession and cultivation.

Several agencies are reportedly working together to review the scheduling of cannabis, with a final decision anticipated to come later this year.

The New Jersey Business Action Center (NJBCA) recently announced Tauhid Chappell as the first Executive Director of its Cannabis Training Academy (CTA).

If passed, possession of psilocybin would be legal in certain circumstances in the state.

Sponsored by 17 state lawmakers, House resolution 420 called on federal officials to reschedule cannabis at the federal level.

After the most recent cannabis legalization bill failed to pass the Senate, Governor Sununu issued a statement explaining how legalization could occur instead.

In early March 2023, the US Justice Department launched an online application for individuals who were pardoned for simple possession of cannabis under President Biden's October 6, 2022 proclamation. Applicants can now receive a certificate of proof of their pardon.

The House and Senate introduced a revised bill to mandate Veterans Affairs (VA) to conduct research on the effects of medical cannabis on veterans with post-traumatic stress disorder (PTSD) and chronic pain.

A statement released on Thursday, January 26, 2023 from Dr. Janet Woodcock, the principal deputy commissioner of the Food and Drug Administration (FDA), announced that the FDA will work with Congress in formulating regulatory oversight to balance risk and access for products in the cannabidiol (CBD) market.

On December 2nd, 2022, President Joe Biden signed the Medical Marijuana and Cannabidiol Research Expansion Act, the first piece of standalone cannabis legislation in US history to become law. It will reportedly streamline a new process for cannabis research applications and for manufacturing products for drug development and allow for a larger amount of legal cannabis for research purposes.

The National Institute on Drug Abuse (NIDA) recently posted a notice to Drug Enforcement Agency-approved cannabis manufacturers that they will soon be able to submit applications to supply cannabis for research purposes. Currently, NIDA has only worked with one cannabis farm for the past 50 years–the new cannabis supplier selected by NIDA would be the second federally authorized in the country.

This column discusses where the USDA went wrong in their final rule regarding hemp and how the author thinks it can be fixed.

Here we take a closer look at the cannabis industry in Canada and speak to several Canadians involved in the industry.

A discussion on how extractors need to monitor the chemical processes they perform.

Congress passes the Marijuana Opportunity, Reinvestment, and Expungement (MORE) Act and the Medical Marijuana Research Act in two historic votes, signifying a growing shift toward cannabis legalization.

How will the need for increased testing impact extractors?

Ann M. Brum and Wayne Smith discuss their roles as cannabis advocates fighting for reform and veteran access to medical cannabis.

What does FDA oversight mean for cannabis businesses and the industry as a whole?

The U.S. House of Representatives will be voting on a historic cannabis legalization bill in September, titled the Marijuana Opportunity, Reinvestment, and Expungement (MORE) Act.

The U.S. Department of Agriculture (USDA) recently issued a temporary delay regarding enforcement on two provisions of its hemp regulations (1).

On Tuesday, December 3, 2019, Brazil’s pharmaceutical regulator Avinsa approved regulations for the roll-out of medicinal cannabis-based products.